EAN 2022 | Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial

Messoud Ashina, MD, PhD, University of Copenhagen, Copenhagen, Denmark, explains the DELIVER trial (NCT04418765), one of the latest Phase III trials on anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraines. The trial specifically looks at the effects of eptinezumab in difficult to treat patients, defined as patients with 2-4 previous failures with migraine preventive medications. Eptinezumab has been shown to be efficacious in previous Phase II and some Phase III studies and thus, the DELIVER trial aimed to build on these findings, extending our understanding of the agent to a difficult to treat population. The result of the DELIVER trial showed that eptinezumab was efficacious in this population, based on patients’ reduction in monthly migraine days, while also showing tolerability and safety. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.